Vera Therapeutics VERA Atacicept For Ig AN — Debt Instrument Face Amount
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtInstrumentFaceAmount.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
On June 2, 2025, the Company entered into a new non-revolving loan and security agreement (2025 Loan Agreement) with a loan syndicate involving Oxford Finance, OFCF II, OFCF III, and Oxford Finance Credit Fund IV LP (OFCF IV) (collectively, Oxford). The 2025 Loan Agreement has a total borrowing capacity of up to $500.0 million, of which $75.0 million was funded at closing and $50.0 million remains available for draw at the Company’s discretion from January 1, 2026, through December 31, 2026. The Company also has the option to draw up to $75.0 million upon accelerated approval of atacicept in immunoglobulin A nephropathy (IgAN), two tranches of a maximum of $50.0 million upon achievement of certain commercial milestones related to atacicept in IgAN once approved, and up to $200.0 million available at the mutual discretion of the Company and Oxford. As of March 31, 2026, the Company’s outstanding borrowing under the 2025 Loan Agreement was $75.0 million.
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's atacicept for ig AN — debt instrument face amount?
- Vera Therapeutics (VERA) reported atacicept for ig AN — debt instrument face amount of $75M in Q2 2025.
- What does atacicept for ig AN — debt instrument face amount mean?
- This metric represents the total principal amount of debt obligations specifically allocated to or secured by the development program for a clinical-stage therapeutic candidate. It reflects the committed financial leverage utilized to fund research, clinical trials, and operational activities for this specific product line. Monitoring this figure helps investors assess the capital structure and debt burden associated with a company's primary drug development assets.
Ask your AI about Vera Therapeutics's atacicept for ig an — debt instrument face amount.
Connect your AI assistant and compare it to peers, right in your chat.
